Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL)

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLauren SchaffMemorial Sloan Kettering Cancer CenterRMRachna MalaniMemorial Sloan Kettering Cancer CenterJSJacqueline StoneMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows 83% complete response rate in newly diagnosed primary CNS lymphoma with ibrutinib and R-MPV, suggesting effective treatment.

Key Points

  • This research aimed to evaluate the efficacy and safety of combining ibrutinib with the R-MPV regimen in newly diagnosed primary CNS lymphoma.
  • Phase 2 trial with eligible patients aged 18 and older with newly diagnosed primary CNS lymphoma.
  • Patients received treatment over four 28-day cycles including rituximab, methotrexate, vincristine, procarbazine, and ibrutinib.
  • Primary endpoint was complete response rate after induction, with secondary endpoints including safety, progression-free survival, and overall survival.
  • 30 patients enrolled, achieving a 83% complete response rate with 25 patients having a complete response and 1 having a partial response.
  • Treatment was well tolerated with a high completion rate of the R-MPV/i regimen.
  • No grade 5 toxicity occurred, though 13 instances of grade 4 toxicities were reported.

Cite This Study

Schaff et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de22https://doi.org/10.1182/blood-2025-5458
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma2026 · 3 citations
  2. 2Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)2025 · 2 citations
  3. 3Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up2025 · 2 citations
  4. 4Outcomes of R-MPV followed by ara-c in primary central nervous system lymphoma: A single-center retrospective analysis.2024 · 1 citations
  5. 5Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma2025 · 2 citations